Working together to develop a screening platform to enhance the detection and management of Alzheimer’s disease.
PREDICTOM is an international across sector initiative to bring dementia diagnostics closer to the public through a customisable cognitive and biomarker screening platform.
Latest news
News
PREDICTOM Level 2 Clinical Study has started
The PREDICTOM is pleased to announce the launch of Level 2 of its international clinical study—an important next step made possible entirely through the generosity, time, and commitment of participants across Europe. The participants' contributions continue to drive forward our shared goal: improving the early detection of Alzheimer’s disease through accessible, reliable, and science-driven tools.
News
📢 PREDICTOM Study Progress
Every contribution tells a story—and together, we’re shaping the future of brain health.
News
☝️Finger-Prick Blood Test Could Revolutionize Early Alzheimer’s Detection
A single drop of blood may soon help identify Alzheimer’s disease - even before symptoms appear. Researchers from the PREDICTOM study are exploring a simple, cost-effective finger-prick test that measures a breakthrough biomarker called p-Tau217, offering hope for earlier and more accessible screening. The finger-prick test is included in PREDICTOM Level 1 clinical study.
PREDICTOM Study Progress
This page provides regularly updated information on the progress of the PREDICTOM study for everyone interested in following its development. The tracker will show progress for both Level 1 and Level 2 as the study advances.
Our mission
PREDICTOM will identify scalable biosignatures for early and accurate diagnosis of Alzheimer’s disease and personalized preventive interventions.